C-H3U4Mirscience Therapeutics
microRNA, oligonucleotides, MIR-Discovery
modulatingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-H3U4
C-H3U4C-H3U4microRNA, oligonucleotides, MIR-Discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Mirscience Therapeutics microRNA, oligonucleotides, MIR-Discovery
Mirscience Therapeutics develops therapies for diseases associated with longevity. Its MIR-Discovery platform identifies therapeutic targets linked to each disease and develops microRNA-based oligonucleotides that act on those targets. The company describes its first molecule, MT-29, as having regenerative and hypertrophic effects on muscle mass for diseases causing atrophy and frailty.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Mirscience Therapeutics — Far from goals · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (2 programs at exploratory).…
Source: Deterministic